-
Thapsigargin for Reproducible Cell Assays
2026-09-15
Learn how Thapsigargin (SKU B6614) helps researchers connect SERCA inhibition with calcium signaling, ER stress, apoptosis, and cell viability outcomes. This scenario-based guide covers assay design, optimization, interpretation, and practical product-selection criteria.
-
Hydrocortisone Butyrate: From GR Biology to Delivery
2026-09-15
Hydrocortisone butyrate is more than a glucocorticoid receptor agonist for inflammation assays. This guide connects receptor biology, dermatitis and epidermal models, and PLGA-based delivery research while showing why ester stability and exposure design determine translational interpretation.
-
MK 0893: From Receptor Binding to In Vivo Readouts
2026-09-14
MK 0893 is a glucagon receptor antagonist whose allosteric pharmacology connects nanomolar receptor binding with measurable metabolic effects. This article offers an assay-to-animal framework for interpreting MK 0893 in type 2 diabetes research, with emphasis on endpoint selection, selectivity, and translational limits.
-
N2703 for Causal Cardiac Signaling Assays
2026-09-14
Explore how 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) can be evaluated in mechanism-focused cardiac models without overstating its biology. This guide translates adipose-neural arrhythmia research into rigorous assay design, controls, and interpretation.
-
Structural Insights into CD38 CAR Affinity Tuning
2026-09-13
This iScience study compares how the CAR binders RP02 and 028 engage CD38, revealing distinct epitope geometries, effects on enzymatic activity, and opportunities for rational affinity tuning. Its affinity-attenuated 028R103G design reduced CAR-T fratricide while preserving cytotoxicity against CD38-positive tumor cells, supporting structure-guided optimization of CD38-directed therapy.
-
Gap26 Connexin 43 Mimetic Peptide Guide
2026-09-12
Gap26 is a connexin 43 mimetic peptide that inhibits Cx43 hemichannel and gap junction communication. It supports controlled studies of calcium signaling modulation, ATP release inhibition, vascular smooth muscle research, and gap junction-dependent mitochondrial transfer.
-
DDI2–NFE2L1 Protects Cells from Ferroptosis
2026-09-12
The reference study identifies DDI2-mediated activation of NFE2L1 as an adaptive response that restores proteasome function during ferroptosis. Its combination of site-specific ubiquitylation proteomics, genetic perturbation, and chemical validation shows how failure of this pathway increases proteotoxic stress and ferroptotic cell death.
-
Rotenone Workflows for Mitochondrial Stress Research
2026-09-11
Rotenone provides a controlled way to connect Complex I inhibition with mitochondrial ROS, ATP loss, and regulated cell death. This guide translates those effects into practical cardiac, neuronal, and pathway-focused workflows, with assay controls that help separate pyroptosis, ferroptosis, apoptosis, and autophagy responses.
-
2-NBDG for Mechanistic Glucose Uptake Assays
2026-09-11
Learn how 2-NBDG converts glucose transporter activity into a resolvable fluorescent phenotype and how to interpret it alongside glycolysis, cell-state, and m6A studies. This guide emphasizes assay design for mechanistic cancer metabolism research rather than uptake measurement alone.
-
From Ferroptosis Signals to Cell Viability Decisions
2026-09-10
Mechanistic oncology studies increasingly need phenotypic assays that connect pathway disruption with actual cell fate. This article examines how Calcein AM/PI staining can complement ferroptosis research in triple-negative breast cancer, while clarifying what a dual-fluorescence viability readout can—and cannot—prove.
-
Clasto-Lactacystin β-lactone: A Causal Assay Lens
2026-09-10
Clasto-Lactacystin β-lactone is more than a proteasome inhibitor: it can serve as a causal perturbation tool for distinguishing proteasome-dependent protein loss from upstream regulation. This article applies that logic to viral RIPK3 degradation and broader ubiquitin-proteasome pathway research.
-
In Vitro Drug Response Metrics in Cancer
2026-09-09
Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability are not interchangeable measures of anticancer response: one combines growth inhibition with death, whereas the other focuses specifically on cell killing. The work supports reporting both dimensions, while accounting for differences in response magnitude and timing when interpreting in vitro drug screens.
-
Parthenolide, ROS, and Apoptosis in Lymphoid Malignancies
2026-09-09
Jorge and colleagues show that parthenolide reduces metabolic activity and promotes oxidative-stress-associated apoptosis across diverse B- and T-lineage lymphoid malignancy models. The study’s main contribution is an integrated comparison of viability, mitochondrial, redox, apoptotic, signaling, and transcriptional endpoints, while also showing that the detailed response mechanism varies by cell line.
-
Comparative Gene Expression in the Mammalian Claustrum
2026-09-08
The reference study combines gene expression, cytoarchitecture, and anatomical position to compare claustrum subdivisions across rats, shrews, tree shrews, marmosets, and macaques. Its findings support conserved molecular and spatial organization across substantially different mammalian brains, while also clarifying why claustrum homology cannot be inferred from a single marker or species.
-
Tropifexor and the Next Frontier of FXR Barrier Research
2026-09-08
Tropifexor (LJN452) offers a powerful way to interrogate how FXR activation connects bile acid biology with intestinal defense and epithelial integrity. This thought-leadership analysis translates neonatal piglet and patient-derived organoid findings into a practical framework for mechanistic, translational, and model-selection decisions.